|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:activeIngredient
|
gptkb:anthrax_vaccine_adsorbed
|
|
gptkbp:approvedBy
|
gptkb:U.S._Food_and_Drug_Administration
1970
|
|
gptkbp:ATCCode
|
J07AX01
|
|
gptkbp:boosterRecommended
|
yes
|
|
gptkbp:contains
|
saline
aluminum hydroxide
anthrax protective antigen
benzethonium chloride
formaldehyde
|
|
gptkbp:contraindication
|
severe allergic reaction to previous dose
hypersensitivity to any component
|
|
gptkbp:countryOfOperation
|
gptkb:United_States
|
|
gptkbp:form
|
suspension for injection
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
BioThrax
|
|
gptkbp:indication
|
post-exposure prophylaxis of anthrax
pre-exposure prophylaxis of anthrax
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Emergent_BioSolutions
|
|
gptkbp:marketedAs
|
gptkb:Anthrax_Vaccine_Adsorbed
|
|
gptkbp:regimen
|
3 doses for post-exposure
series of 5 doses for pre-exposure
|
|
gptkbp:riskFactor
|
fatigue
headache
muscle aches
allergic reactions
injection site reactions
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
subcutaneous injection
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:targetAudience
|
gptkb:military
laboratory workers
certain at-risk civilians
|
|
gptkbp:usedFor
|
prevention of anthrax
|
|
gptkbp:bfsParent
|
gptkb:Anthrax_Vaccine_Adsorbed_(AVA)
|
|
gptkbp:bfsLayer
|
4
|